High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Heart Journal

• Publication date

  2002-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1067/MHJ.2002.130301PMID 12486414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial

  2003cited by this paper
• Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins.

  2002cited by this paper
• Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Ezetimlbe co-administered With slmvastatin in 668 patients With primary hypercholesterolemia

  2002cited by this paper
• Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia

  2002cited by this paper
• Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I

  2001cited by this paper
• Structure of the human acyl-CoA:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia.

  2001cited by this paper
• A risk factor for atherosclerosis: triglyceride-rich lipoproteins.

  2001cited by this paper
• Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

  2001cited by this paper
• Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

  2001cited by this paper
• Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis.

  2001cited by this paper
• Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.

  2001cited by this paper
• Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression.

  2001cited by this paper
• Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

  2001cited by this paper
• Current Concepts of the Pathogenesis of the Acute Coronary Syndromes

  2001cited by this paper
• HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

  2001cited by this paper
• High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection

  2001cited by this paper
• Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids

  2001cited by this paper
• Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein*

  2001cited by this paper
• Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II

  2001cited by this paper
• Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

  2000cited by this paper
• Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

  2000cited by this paper
• A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

  2000cited by this paper
• Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators

  2000cited by this paper
• Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography.

  2000cited by this paper
• The role of small, dense low density lipoprotein (LDL): a new look.

  2000cited by this paper
• Role of serum amyloid A during metabolism of acute-phase HDL by macrophages.

  2000cited by this paper
• HDL modification by secretory phospholipase A(2) promotes scavenger receptor class B type I interaction and accelerates HDL catabolism.

  2000cited by this paper
• Evidence that triglycerides are an independent coronary heart disease risk factor.

  2000cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Emerging concepts in metabolic abnormalities associated with coronary artery disease

  2000cited by this paper
• Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.

  2000cited by this paper
• High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

  2000cited by this paper
• Acute-phase proteins and other systemic responses to inflammation.

  1999cited by this paper
• PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells

  1999cited by this paper
• Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

  1999cited by this paper
• PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

  1999cited by this paper
• PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease

  1999cited by this paper
• Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• Elevated C-reactive protein levels in overweight and obese adults.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

  1998cited by this paper
• Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

  1998cited by this paper
• Comparison of statins in hypertriglyceridemia.

  1998cited by this paper
• Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

  1998cited by this paper
• Acute respiratory-tract infections and risk of first-time acute myocardial infarction.

  1998cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL.

  1998cited by this paper
• Management of Dyslipidemia in Adults With Diabetes

  1998cited by this paper
• Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research.

  1997cited by this paper
• Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies

  1996cited by this paper
• Symptoms of chronic bronchitis and the risk of coronary disease.

  1996cited by this paper
• Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men.

  1996cited by this paper
• Plasma Platelet-activating Factor Acetylhydrolase Is a Secreted Phospholipase A2 with a Catalytic Triad (*)

  1995cited by this paper
• Transactivation by PPAR/RXR heterodimers in yeast is potentiated by exogenous fatty acid via a pathway requiring intact peroxisomes.

  1995cited by this paper
• Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.

  1994cited by this paper
• Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: a concept.

  1994cited by this paper
• Plasma triglyceride level and mortality from coronary heart disease.

  1993cited by this paper
• Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.

  1993cited by this paper
• Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment.

  1992cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment

  1992cited by this paper
• Influence of serum amyloid A on cholesterol esterification in human plasma.

  1989cited by this paper
• High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

  1989cited by this paper
• High-density lipoprotein--the clinical implications of recent studies.

  1989cited by this paper
• Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

  1988cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• The triglyceride issue: a view from Framingham.

  1986cited by this paper

• The Influence of Exemestane on the Lipid Profile in Breast Cancer Patients: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

  2025cites this paper
• Cardiovascular Consequences Unveiled: A Comprehensive Review of Hypopituitarism's Impact on the Heart.

  2025cites this paper
• Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients

  2024cites this paper
• The effect of exemestane administration on the lipid profile in women: Meta-analysis of randomized controlled trials.

  2024cites this paper
• Prenatal nursing care is essential! Breastfeeding: focus on maternal health

  2023cites this paper
• Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders

  2023cites this paper
• Exergaming Improves Cardiac Risk Factors in Prostate Cancer Patients: A Single-Blinded Randomized Controlled Trial

  2023cites this paper
• Dietary supplementation with casein/cyanidin-3-O-glucoside nanoparticles alters the gut microbiota in high-fat fed C57BL/6 mice.

  2023cites this paper
• Cholesterol and its biological significance. Atherosclerosis. Statin therapy (Part 1)

  2022cites this paper
• Comparative lipid and uric acid suppressing properties of four common herbs in high fat-induced obese mice with their total phenolic and flavonoid index

  2021cites this paper
• The Effect of Pilates Training on Body Composition, Lipid Profile, and Serum 25-Hydroxy Vitamin D Levels in Inactive Overweight Women

  2021cites this paper
• Hypoglycemic, Hypolipidemic and Antioxidant Activities of Ocimum gratissimum Leaf Extract on Diabetic Rats

  2021cites this paper
• The Effect of Short–Term Nanocurcumin Supplementation on the Anthropometric Indices, Lipid Profile and C-Reactive Protein of Overweight Girls

  2020cites this paper
• Dose 12 week resistance training Influence IL-18 and CRP levels in Elderly men?

  2018cites this paper
• Can Vitamin D Deficiency Predict Coronary Artery Disease

  2018cites this paper
• آیا 12 هفته تمرینات مقاومتی بر سطوح IL-18 وCRP مردان سالمند تاثیر دارد؟

  2018cites this paper
• Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors

  2018cites this paper
• Nontraditional Lipid Variables Predict Recurrent Brain Ischemia in Embolic Stroke of Undetermined Source.

  2017cites this paper
• Review of Garcinia mangostana and its Xanthones in Metabolic Syndrome and Related Complications

  2017cites this paper
• Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study

  2017cites this paper
• Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries

  2017cites this paper
• Acceptability, short term impacts, and relationships of variables of a processed foods module

  2016cites this paper
• Glycemic Index and Macrovascular Disease in Type 2 Diabetes

  2016cites this paper
• SOYFOODS MAY OFFER SIGNIFICANT HEALTH BENEFITS TO MEN, SUCH AS LOWERING THE RISK OF PROSTATE CANCER, HEART DISEASE AND MORE. AS THIS FACT SHEET WILL DISCUSS, MEN NEED NOT FEAR THE RISK OF FEMINIZATION

  2016cites this paper
• Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

  2015cites this paper
• Pharmacogenetics and Statin Treatment: Reality or Theory?

  2015cites this paper
• Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

  2015cites this paper
• Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

  2015cites this paper
• A Conversion Protocol for Simvastatin and Gemfibrozil

  2014cites this paper
• PERAN KOLESTEROL HDL TERHADAP PENYAKIT KARDIOVASKULER DAN DIABETES MELLITUS

  2014cites this paper
• HYPOLIPIDAEMIC EFFECTS OF AQUEOUS EXTRACT OF SANSEVIERIA LIBERICA LEAVES EXTRACTS IN HYPERCHOLESTEROLAEMIA RATS

  2014cites this paper
• SOY MEN ’ S HEALTH

  2014cites this paper
• Dietary Quality among Tehranian Adults in Relation to Lipid Profile: Findings from the Tehran Lipid and Glucose Study

  2013cites this paper
• Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)

  2013cites this paper
• “When Diet and Exercise Are Not Enough”: An Examination of Lifestyle Change Inefficacy Claims in Direct-to-Consumer Advertising

  2013cites this paper
• Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

  2013cites this paper
• Statins and primary prevention of cardiovascular diseases: is there any point?

  2013cites this paper
• Cilostazol Inhibits Accumulation of Triglyceride in Aorta and Platelet Aggregation in Cholesterol-Fed Rabbits

  2012cites this paper
• in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study)

  2012cites this paper
• Can breast cancer patients use soyafoods to help reduce risk of CHD?

  2012cites this paper
• Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

  2012cites this paper
• THE COMPARISON OF TWO METHODS OF INTERMITTENCE AND CONTINUATIVE EXERCISE ON HS-CRP AND LIPIDS AS PREDICTORS OF HEART DISEASE – CORONARY

  2012cites this paper
• Pregnancy during adolescence has lasting adverse effects on blood lipids

  2012cites this paper
• Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

  2012cites this paper
• Extended-Release Niacin/Laropiprant Significantly Improves Lipid Levels in Type 2 Diabetes Patients Irrespective of Baseline Glycemic Control

  2012cites this paper
• Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus

  2012cites this paper
• Influencia de la lactancia materna en el futuro riesgo cardiovascular de la mujer

  2012cites this paper
• Pregnancy during adolescence has lasting adverse effects on blood lipids: a 10-year longitudinal study of black and white females.

  2012cites this paper
• Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.

  2012cites this paper
• Antioxidant SMe1EC2 may attenuate the disbalance of sodium homeostasis in the organism induced by higher intake of cholesterol

  2012cites this paper
• South African consumers' opinions and beliefs regarding the health benefits of soy and soy products

  2011cites this paper
• Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.

  2011cites this paper
• Persistent Dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events – Results of the dyslipidemia international study (DYSIS)

  2011cites this paper
• Extended‐release niacin/laropiprant lipid‐altering consistency across patient subgroups

  2011cites this paper
• Development of Formulas for Estimation of Cholesterol Levels in Major Serum Lipoproteins Separated by Agarose Gel Electrophoresis

  2011cites this paper
• Combination therapy with ezetimibe/simvastatin versus statin monotherapy for low-density lipoprotein cholesterol reduction and goal attainment in a real-world clinical setting.

  2011cites this paper
• Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia.

  2011cites this paper
• Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.

  2010cites this paper
• Risk Factors Preceding Type 2 Diabetes and Cardiomyopathy

  2010cites this paper
• Trend of Prevalence of Low HDL-Cholesterol and Related Factors in Korean Men: Using 3 Korean National Health and Nutrition Examination Survey Data (1998-2005)

  2010cites this paper
• Effect of pomegranate seed oil on hyperlipidaemic subjects: a double-blind placebo-controlled clinical trial

  2010cites this paper
• Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

  2010cites this paper
• Effects of Aspirin When Added to the Prostaglandin D2 Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms

  2009cites this paper
• Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.

  2009cites this paper
• Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

  2009cites this paper
• Evaluation of genetic risk scores for lipid levels using genome-wide markers in the Framingham Heart Study

  2009cites this paper
• Novel rare alleles of ABCA1 are exclusively associated with extreme high-density lipoprotein-cholesterol levels among the Han Chinese

  2009cites this paper
• CHAPTER 37 – Special Patient Populations: Diabetes and Metabolic Syndrome

  2009cites this paper
• Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

  2009influential citation
• Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2008cites this paper
• Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.

  2008cites this paper
• Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes

  2008cites this paper
• Current world literature. Arrhythmias.

  2008cites this paper
• Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus.

  2008cites this paper
• Lipoproteína(A) e massa corporal de ratos submetidos à hipercolesterolemia e treinamentos físicos de força e aeróbico

  2008cites this paper
• Treatment Goals for the Management Treatment Goals for the Management of Lipids and Inflammation for Patients of Lipids and Inflammation for Patients with Coronary Artery Disease with Coronary Artery Disease

  2007cites this paper
• Therapeutic angiogenesis

  2007cites this paper
• Management of hypertriglyceridemia.

  2007cites this paper
• Risk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III

  2007cites this paper
• Soy protein, soybean isoflavones and coronary heart disease risk: where do we stand?

  2007cites this paper
• Lactation and Changes in Maternal Metabolic Risk Factors

  2007cites this paper
• Treatment goals for the management of lipids and inflammation for patients with coronary artery disease

  2007cites this paper
• Stearoyl-Coenzyme A Desaturase 1 Deficiency Protects against Hypertriglyceridemia and Increases Plasma High-Density Lipoprotein Cholesterol Induced by Liver X Receptor Activation

  2006cites this paper
• Prevalence of low HDL‐cholesterol in patients with cardiovascular risk factors: the ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey

  2006cites this paper
• The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.

  2006cites this paper
• Less than 50% of variation in HDL cholesterol between and within individuals, is explained by established predictors.

  2006cites this paper
• Aromatase inhibitors as adjuvant treatment of breast cancer.

  2006cites this paper
• Inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease

  2006cites this paper
• Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

  2006cites this paper
• Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels

  2006cites this paper
• [Relationship between coronary risk calculation and distribution of the coronary artery lesions and risk factors].

  2006cites this paper
• Applied nutritional investigation Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women

  2006cites this paper
• Fibrates in Combination With Statins in the Management of Dyslipidemia

  2006cites this paper
• Exemestane for breast cancer prevention: a feasible strategy?

  2005cites this paper
• Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients

  2005cites this paper
• Generating Genetic Risk Scores from Intermediate Phenotypes for Use in Association Studies of Clinically Significant Endpoints

  2005cites this paper
• Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia

  2005cites this paper
• Therapeutic angiogenesis for coronary artery disease: clinical trials of proteins, plasmids, adenovirus and stem cells.

  2005cites this paper
• Fasting apoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia.

  2005cites this paper
• Comparison of Serum Lipid Values in Patients With Coronary Artery Disease at 70 Years of Age

  2005cites this paper